Pyrazolopyrimidines: A Promising Frontier in Cancer Treatment‐Reviewing Their Potential as Inhibitors of Serine/Threonine Kinases

Abstract

Pyrazolopyrimidine derivatives have emerged as potent inhibitors targeting a broad spectrum of kinases, particularly serine/threonine kinases (STK). This review provides a comprehensive overview of the structural modifications and pharmacological relevance of pyrazolopyrimidine compounds in the realm of kinase inhibition. Specifically, the focus is placed on their inhibitory action against STK, key players in cell signaling and potential therapeutic targets in various diseases, especially cancer. The structure-activity relationship (SAR) of these derivatives highlights the importance of specific substituents in enhancing inhibitory activity, and pyrazolopyrimidine derivatives have shown promising inhibitory activity against certain STK. Challenges remain, including issues related to drug resistance, off-target effects, and potential toxicity. Future research is geared toward designing more selective derivatives with improved pharmacokinetic properties and reduced side effects.